Early cancer detection is a key determinant of patient survival, but scientists struggle to identify reliable biomarkers and diagnostic tools. Researchers recently discovered cancer-specific glycosylation signatures that promote tumor progression. Because protein glycosylation controls cellular behaviors such as cell adhesion and migration, altered glycosylation states render cancer cells more invasive. In this webinar, brought to you by Vector Laboratories, Karen Abbott and Susan Bellis will discuss how cancer cells modify glycosylation pathways to survive, and how to target tumor-specific glycans for early cancer detection, prognosis, and therapeutic development.
Topics to be covered
Tools and technologies to detect glycan biomarkers
How cancer-induced receptor glycosylation activates tumorigenic pathways
The therapeutic potential of tumor-selective glycans
Monday, December 6, 2021
3:00 - 4:30 PM Eastern Time
Meet the speakers
Karen Abbott, PhD Associate Professor Department of Translational Medicine Herbert Wertheim College of Medicine Florida International University
Susan L. Bellis, PhD Professor Department of Cell, Developmental, and Integrative Biology University of Alabama at Birmingham
TS_WEBINAR_Vector Labs Labtools_December 6, 2021
Information you provide will be shared with the sponsors for this content. The Scientist or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
The Scientist c/o LabX Media Group 1000 N West Street, Suite 1200, Wilmington, Delaware, United States, 19801 Toll Free: 888.788.0328 | Phone: 705.528.6888 Email: email@example.com